文献速递流行病学与生物统计临床试验与 GCP新药、器械与细胞基因治疗研发

儿童耐多药结核病的治疗与结局:系统综述与个体患者数据荟萃分析

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
PubMed 文献 · PLoS Med · 2018-07-11

该研究为修订WHO儿童MDR-TB治疗指南提供依据,检索多个数据库至2014年10月,纳入33项观察性队列研究(28项提供个体患者数据),分析18个国家975名儿童。总体78%获得治疗成功,确诊MDR-TB者75%、临床诊断者89%;HIV感染儿童未接受ART者成功率仅56%,接受ART者为82%。

要点

  • 儿童MDR-TB总体治疗成功率78%,临床诊断者高于细菌学确诊者。
  • HIV感染儿童在MDR-TB治疗期间接受ART与更高治疗成功率相关。
  • 确诊MDR-TB儿童中,二线注射剂和高剂量异烟肼与治疗成功相关。

核心结论

  • 儿童对MDR-TB治疗反应总体良好,HIV感染儿童治疗期间未接受ART者成功率低,提示需给予ART。
  • 个别药物对治疗结局的影响需进一步评估。

研究设计与样本

  • 系统综述与个体患者数据荟萃分析,为修订WHO儿童MDR-TB治疗指南提供依据。
  • 检索PubMed、LILACS、Embase、Cochrane Library、PsychINFO、BioMedCentral至2014年10月1日,并检索会议摘要与未发表数据。
  • 纳入标准为至少3名15岁以下接受MDR-TB治疗的儿童且报告治疗结局;共33项研究符合条件,28项提供个体患者数据。
  • 分析975名来自18个国家的儿童,731名(75%)细菌学确诊、244名(25%)临床诊断,中位年龄7.1岁。
  • 910名(93%)有HIV状态记录,其中359名(39%)感染HIV;全部数据来自观察性队列。

主要发现

  • 975名儿童中764名(78%)治疗成功:确诊者548/731(75%),临床诊断者216/244(89%),绝对差14%(95%CI 8%-19%,p<0.001)。
  • 确诊MDR-TB儿童较临床诊断者更可能年龄较大、感染HIV、营养不良及胸片示严重结核(各特征p<0.001)。
  • 确诊MDR-TB且感染HIV的儿童中,治疗期间未接受ART者成功率56%,接受ART者82%(绝对差26%,95%CI 5%-48%,p=0.006)。
  • 确诊MDR-TB儿童中,使用二线注射剂与治疗成功相关(aOR 2.9,95%CI 1.0-8.3,p=0.041)。
  • 确诊MDR-TB儿童中,高剂量异烟肼(15-20 mg/kg/天)与治疗成功相关(aOR 5.9,95%CI 1.7-20.5,p=0.007),但可能受中心效应影响,多数患者来自开普敦。

关键数值与推荐

  • 治疗成功定义按原文报告的治疗结局判定,总体成功率为78%(764/975)。
  • HIV感染儿童在MDR-TB治疗期间接受ART者成功率82%,未接受者56%(绝对差26%,95%CI 5%-48%,p=0.006)。
  • 二线注射剂与治疗成功的aOR为2.9(95%CI 1.0-8.3,p=0.041)。
  • 高剂量异烟肼15-20 mg/kg/天与治疗成功的aOR为5.9(95%CI 1.7-20.5,p=0.007)。

临床怎么用

  • 儿童MDR-TB治疗应关注HIV感染状态,治疗期间应给予ART以改善治疗结局。
  • 二线注射剂和高剂量异烟肼(15-20 mg/kg/天)可能与更高治疗成功率相关,可结合指南与个体情况考虑。
  • 临床诊断与细菌学确诊儿童的治疗成功率存在差异,评估结局时需区分诊断依据。

局限性

  • 难以估计多药方案中单个药物的治疗效应。
  • 仅能纳入观察性队列研究。
  • 治疗决策基于临床医生对病情的判断,可能存在偏倚。
  • 高剂量异烟肼的发现可能受中心效应影响,多数患者来自开普敦。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optimal treatment for these children. METHODS AND FINDINGS: To inform the pediatric aspects of the revised World Health Organization (WHO) MDR-TB treatment guidelines, we performed a systematic review and individual patient data (IPD) meta-analysis, describing treatment outcomes in children treated for MDR-TB. To identify eligible reports we searched PubMed, LILACS, Embase, The Cochrane Library, PsychINFO, and BioMedCentral databases through 1 October 2014. To identify unpublished data, we reviewed conference abstracts, contacted experts in the field, and requested data through other routes, including at national and international conferences and through organizations working in pediatric MDR-TB. A cohort was eligible for inclusion if it included a minimum of three children (aged <15 years) who were treated for bacteriologically confirmed or clinically diagnosed MDR-TB, and if treatment outcomes were reported. The search yielded 2,772 reports; after review, 33 studies were eligible for inclusion, with IPD provided for 28 of these. All data were from published or unpublished observational cohorts. We analyzed demographic, clinical, and treatment factors as predictors of treatment outcome. In order to obtain adjusted estimates, we used a random-effects multivariable logistic regression (random intercept and random slope, unless specified otherwise) adjusted for the following covariates: age, sex, HIV infection, malnutrition, severe extrapulmonary disease, or the presence of severe disease on chest radiograph. We analyzed data from 975 children from 18 countries; 731 (75%) had bacteriologically confirmed and 244 (25%) had clinically diagnosed MDR-TB. The median age was 7.1 years. Of 910 (93%) children with documented HIV status, 359 (39%) were infected with HIV. When compared to clinically diagnosed patients, children with confirmed MDR-TB were more likely to be older, to be infected with HIV, to be malnourished, and to have severe tuberculosis (TB) on chest radiograph (p < 0.001 for all characteristics). Overall, 764 of 975 (78%) had a successful treatment outcome at the conclusion of therapy: 548/731 (75%) of confirmed and 216/244 (89%) of clinically diagnosed children (absolute difference 14%, 95% confidence interval [CI] 8%-19%, p < 0.001). Treatment was successful in only 56% of children with bacteriologically confirmed TB who were infected with HIV who did not receive any antiretroviral treatment (ART) during MDR-TB therapy, compared to 82% in children infected with HIV who received ART during MDR-TB therapy (absolute difference 26%, 95% CI 5%-48%, p = 0.006). In children with confirmed MDR-TB, the use of second-line injectable agents and high-dose isoniazid (15-20 mg/kg/day) were associated with treatment success (adjusted odds ratio [aOR] 2.9, 95% CI 1.0-8.3, p = 0.041 and aOR 5.9, 95% CI 1.7-20.5, p = 0.007, respectively). These findings for high-dose isoniazid may have been affected by site effect, as the majority of patients came from Cape Town. Limitations of this study include the difficulty of estimating the treatment effects of individual drugs within multidrug regimens, only observational cohort studies were available for inclusion, and treatment decisions were based on the clinician's perception of illness, with resulting potential for bias. CONCLUSIONS: This study suggests that children respond favorably to MDR-TB treatment. The low success rate in children infected with HIV who did not receive ART during their MDR-TB treatment highlights the need for ART in these children. Our findings of individual drug effects on treatment outcome should be further evaluated.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018. PMID: 29995958. doi:10.1371/journal.pmed.1002591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。